Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945851 | 0.79 | — | — | |
| SCHEMBL24383368 | 0.78 | MLYCD (0.42) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL23945444 | 0.74 | — | — | |
| SCHEMBL22606070 | 0.71 | CYP2D6 (0.31) | CYP2D6CYP2C19 | |
| SCHEMBL18610515 | 0.70 | — | — | |
| SCHEMBL18624716 | 0.70 | — | — | |
| SCHEMBL23945891 | 0.70 | EPHX1 (0.33) | EPHX1KMT2A | |
| SCHEMBL22861775 | 0.70 | EPHX1 (0.33) | EPHX1KMT2A | |
| SCHEMBL23945680 | 0.70 | EPHX1 (0.33) | EPHX1KMT2A | |
| SCHEMBL20070641 | 0.70 | CYP2D6 (0.34) | CYP2D6CYP2C19MMP1MMP8CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200230249-A1 | PEPTIDE-OLIGOUREA HYBRID COMPOUNDS | UREKA SARL (FR) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CYP2D6 2573/4885CYP2C19 4360/4885MMP1 4152/4885 |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CYP2D6 2573/4885CYP2C19 4360/4885MMP1 4152/4885 |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | CYP2D6 2314/4885CYP2C19 4173/4885MMP1 4169/4885 |
| US-20200230249-A1 | PEPTIDE-OLIGOUREA HYBRID COMPOUNDS | IAPP, NGLY1, NPPA | CYP2D6 4766/4885CYP2C19 4792/4885MMP1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.